In 2019, Jeffrey L. Cummings, MD, ScD, joined the UNLV School of Integrated Health Science as a research professor in the Department of Brain Health. Dr. Cummings is ranked in the top 0.01% of scientists, and #5 in Alzheimer’s disease research in a recent publication in PLoS Biology. He is a world-renowned Alzheimer’s researcher and leader of clinical trials.
Prior to UNLV, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, and as director of the Mary S. Easton Center for Alzheimer’s Disease Research, and director of the Deane F. Johnson Center for Neurotherapeutics, both at UCLA.
Dr. Cummings is the inaugural holder of the Chambers-Grundy Center for Transformative Neuroscience Professorship. He is a leader in Alzheimer’s disease (AD) clinical trials and academic aspects of drug development. His more than 800 peer-reviewed academic peer-reviewed publications and 44 books address Alzheimer’s disease, Parkinson’s disease, NDD, clinical trials, and treatment development. He is deeply committed to discovery of methods for accelerating the development of new and transformative treatments for brain diseases. His papers on drug development are among the most widely cited in the field and have become influential in drug development programs in both academics and the biotechnology industry.
While continuing to lead some research efforts at the LRCBH, Dr. Cummings has assumed a major role in the UNLV Department of Brain Health as Vice Chair for Research. His responsibilities as the director of the Chambers-Grundy Center are to collaborate with Dr. Jefferson W. Kinney, the founding chair of the Department of Brain Health, and Dr. Kate Zhong, adjunct professor and Brainnovation founder, to create the Center’s vision and mission.